Calidi Biotherapeutics, Inc. (CLDI) stock
Close on Nov 12, 2026Market cap $1.69MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.54
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$17.47M
- EPS, diluted
- -$5.95
- Book value per share
- $2.21
- Diluted shares
- 1M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $0.68
- Open
- $0.68
- Day's range
- $0.64 – $0.70
- Volume
- 35,224
- Average volume (20 days)
- 46,353
- Beta (5 years)
- 0.52
- 52-week range
- $0.62 – $24.96
- RSI (14 days)
- 36.3
- Volatility (1 year)
- 94.1%
- Relative volume
- 0.16×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLDI | S&P 500 | Difference | CLDI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.0% | -2.7% | −28.3 pts | ||
| 3 months | -59.8% | -1.7% | −58.1 pts | ||
| Year to date | -96.5% | +11.9% | −108.4 pts | ||
| 1 year | -97.3% | +12.0% | −109.3 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -94.5% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -87.2% | +11.6% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Calidi Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity DeficiencyNews
- News
- Results
- Update
- Results
- Results
About Calidi Biotherapeutics
Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The company explores proprietary delivery and expression platforms designed to utilize oncolytic viruses and cell therapies to treat various solid tumors and oncological conditions. Its operations concentrate entirely on research and development activities in the biopharmaceutical space.
Company profile, executives and historyCalidi Biotherapeutics stock: common questions
What is Calidi Biotherapeutics's stock price?
CLDI closed at $0.66 on Nov 12, 2026, down 2.96% on the day. Over the past 52 weeks it traded between $0.62 and $24.96.
What is Calidi Biotherapeutics's market cap?
Calidi Biotherapeutics was worth $1.69M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CLDI's P/E ratio?
Calidi Biotherapeutics lost money over fiscal 2025 (diluted EPS -$5.95), so it has no meaningful P/E ratio.
Does Calidi Biotherapeutics pay a dividend?
No. Calidi Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Calidi Biotherapeutics report earnings next?
Calidi Biotherapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CLDI stock performed over the past year?
Including dividends, CLDI returned -97.3% over the past year, against +12.0% for the S&P 500.
Who are Calidi Biotherapeutics's competitors?
Companies most similar to Calidi Biotherapeutics by business, industry and size include CRDF, CGON, CERO, SAEN, CADL.
See a number that looks wrong?